Gyre Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

San Diego, CA – June 16, 2026 – Gyre Therapeutics, Inc. (NASDAQ: GYRE), a pharmaceutical company based in San Diego, has released the official results of its 2026 Annual Meeting of Stockholders, held on June 10, 2026. The meeting covered the election of directors, executive compensation approval, ratification of auditors, and a critical vote regarding the conversion of preferred stock – all of which may have meaningful implications for shareholders and the company’s future direction.

Key Highlights

• All director nominees were elected to serve until the 2029 Annual Meeting of Stockholders.
• Executive compensation was approved through a non-binding, advisory vote.
• Grant Thornton Zhitong Certified Public Accountants LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
• Shareholders approved the issuance of common stock upon conversion of Series B Preferred Stock, as required by Nasdaq Listing Rule 5635(a).

Detailed Results and Implications for Shareholders

1. Election of Directors

The following Class II director nominees were elected to serve until the 2029 Annual Meeting of Stockholders:

Shareholder Impact: The re-election of experienced directors provides continuity in company leadership and may support ongoing strategic initiatives. However, no new directors or major board changes were made, which may suggest stability rather than immediate change.

2. Non-Binding Advisory Vote on Executive Compensation (“Say-on-Pay”)

Shareholder Impact: Strong support for executive compensation plans may indicate investor confidence in management’s strategy and performance. Still, as this is advisory, it does not require the company to change its compensation practices.

3. Ratification of Independent Auditor

Shareholder Impact: The ratification of Grant Thornton Zhitong Certified Public Accountants LLP ensures continuity in financial oversight and auditing. This is generally seen as a routine but important shareholder approval.

4. Approval of Conversion of Series B Preferred Stock

Shareholder Impact: This is a potentially price-sensitive event. The approval allows for the conversion of Series B Preferred Stock into common stock in accordance with Nasdaq rules. This move could lead to an increase in the number of outstanding common shares, which may have a dilutive effect on existing shareholders. However, it could also strengthen the company’s capital structure or provide needed funding for growth and operations. Investors should monitor subsequent disclosures regarding the number of shares to be issued and any related business plans.

Other Important Shareholder Information

• Common Stock Outstanding and Voting Rights: As of the record date (April 16, 2026), there were 96,994,001 shares of common stock entitled to vote at the meeting.
• Company’s Status: Gyre Therapeutics, Inc. is no longer classified as an “emerging growth company” as per SEC definitions.
• Trading Information: The company’s common stock trades on The Nasdaq Capital Market under the ticker symbol GYRE.

Conclusion and Investor Takeaways

All proposals at the Annual Meeting passed with strong shareholder support. The key actionable event for investors is the approval to convert Series B Preferred Stock into common shares, which could affect share value via dilution or, conversely, provide fresh capital for business initiatives. No board shakeups or changes in auditor occurred, suggesting ongoing stability. Investors should watch for further company updates regarding the implementation of the preferred stock conversion and any related strategic developments.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should consult their own advisors before making investment decisions. The information provided is based on company filings and public disclosures as of June 2026 and may be subject to change without notice.

View GYRE THERAPEUTICS, INC. Historical chart here